AmandaCashenMD

Oncology • Saint Louis, MO

Hematologic Oncology

Associate Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Cashen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cashen's full profile

Already have an account?

Office
4921 Parkview Pl
7th Floor
Saint Louis, MO 63110
Phone+1 314-747-1171

Fax+1 314-362-3192
Is this information wrong?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2003 - 2006
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2002
Washington University in St. Louis School of MedicineClass of 1999

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2000 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Belinostat in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2006 May 01
Completed
Phase 2
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma Start of enrollment: 2005 Feb 01
Completed
Not Applicable
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma Start of enrollment: 2008 Nov 01
Completed
Phase 1, Phase 2
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 May 01
Completed
Phase 1
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma Start of enrollment: 2011 Apr 28
Completed
Phase 1
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma Start of enrollment: 2012 Jul 01
Terminated
Phase 1
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Sep 18
Completed
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2014 Jun 01
Completed
Early Phase 1
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Start of enrollment: 2015 Feb 04
Completed
Phase 1
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

4 citations
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress.
Nancy Issa, Hassan Bjeije, Elisabeth R Wilson, Aishwarya Krishnan, Wangisa M B Dunuwille, Tyler M Parsons, Christine R Zhang, Wentao Han, Andrew L Young, Zhizhong Ren,...> ;Leukemia. 2023 Apr 1
29 citations
Autologous T cell therapy for MAGE-A4solid cancers in HLA-A*02patients: a phase 1 trial.
David S Hong, Brian A Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L Johnson, Anthony J Olszanski, Jeffrey M Clarke, Dejka Araujo, George R Blumenschein Jr, Pa...> ;Nature Medicine. 2023 Jan 1
2 citations
Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival.
Christine Auberle, Daniel Lenihan, Feng Gao, Amanda Cashen> ;Cardio-Oncology. 2023 Jan 6
86 citations
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth M Paietta, Susan O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong Ch...> ;Blood. 2022 Jul 14
5 citations
Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.
Shama Jaswal, Vanessa Sanders, Priyanka Pullarkat, Stephanie Teja, Amber Salter, Marcus P Watkins, Norman Atagu, Daniel R Ludwig, Joyce Mhlanga, Vincent M Mellnick, Li...> ;Cancers. 2022 Jun 14
4 citations
Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.
Pashna N Munshi, Yue Chen, Kwang W Ahn, Farrukh T Awan, Amanda Cashen, Geoffrey Shouse, Mazyar Shadman, Paul Shaughnessy, Joanna Zurko, Frederick L Locke, Aaron M Good...> ;Transplantation and Cellular Therapy. 2022 Aug 1
18 citations
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Lawrence Wayne Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Ramzi Abboud, Peter Westervelt, Camille Abboud, Ravi Vij, Keith Stockerl-Goldstein, Iskra Pusic,...> ;Transplantation and Cellular Therapy. 2022 Aug 1
3 citations
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
R Andrew Harkins, Sharvil P Patel, Michelle J Lee, Jeffrey M Switchenko, Stephen M Ansell, Nancy L Bartlett, Kristie A Blum, Amanda F Cashen, Carla Casulo, Jonathan W ...> ;Blood Advances. 2022 May 10
Stem cell transplant for lymphoma - never too late?
Amanda F Cashen, Nancy L Bartlett> ;Haematologica. 2022 May 1
49 citations
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
Jeffrey J Bednarski, Clare Zimmerman, Melissa M Berrien-Elliott, Jennifer A Foltz, Michelle Becker-Hapak, Carly C Neal, Mark Foster, Timothy Schappe, Ethan McClain, Pa...> ;Blood. 2022 Mar 17
3 citations
Decitabine salvage for-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy.
Francesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, Christopher A Miller, Mary Elizabeth Percival, Geoffrey L Uy, Iskra Pusic, Meagan A Jacoby, Mathew J Christ...> ;Haematologica. 2022 Jul 1
42 citations
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.
Melissa M Berrien-Elliott, Jennifer A Foltz, David A Russler-Germain, Carly C Neal, Jennifer Tran, Margery Gang, Pamela Wong, Bryan Fisk, Celia C Cubitt, Nancy D Marin...> ;Science Translational Medicine. 2022 Feb 23
14 citations
Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics.
Mehdi Hamadani, Maud Ngoya, Anna Sureda, Qaiser Bashir, Carlos Litovich, Herve Finel, Yue Chen, Ariane Boumendil, Jasmine Zain, Luca Castagna, Amanda F. Cashen, Didier...> ;Blood Advances. 2021 Dec 3
13 citations
Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami J. Maddocks, Matthew Mo...> ;Blood. 2021 Nov 15
4 citations
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation
Peter A. Riedell, Mehdi Hamadani, Kwang Woo Ahn, Carlos Litovich, Claudio G. Brunstein, Amanda F. Cashen, Jonathon B. Cohen, Narendranath Epperla, Brian T. Hill, Annie...> ;British Journal of Haematology. 2021 Sep 28
7 citations
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
Eric Huselton, Michael P. Rettig, Kirsten Campbell, Amanda F. Cashen, John F. DiPersio, Feng Gao, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Mark A. Schroeder, Geoff...> ;Leukemia Research. 2021 Nov 1
8 citations
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Trans...
Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad S. Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick ...> ;Transplantation and Cellular Therapy. 2021 Sep 1
1 citations
Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers.
Jared M. Andrews, Sarah C. Pyfrom, Jennifer A. Schmidt, Olivia I. Koues, Rodney A. Kowalewski, Nicholas R. Grams, Jessica J. Sun, Leigh R. Berman, Eric J. Duncavage, Y...> ;Ebiomedicine. 2021 Sep 1
17 citations
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
Pashna N. Munshi, Mehdi Hamadani, Ambuj Kumar, Peter Dreger, Jonathan W. Friedberg, Martin Dreyling, Brad S. Kahl, Mats Jerkeman, Mohamed A. Kharfan-Dabaja, Frederick ...> ;Bone Marrow Transplantation. 2021 Aug 20
17 citations
Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib.
Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta, Susan O'Brien, Jacqueline C. Barrientos, Jose F. Leis, Cong Ch...> ;Blood. 2021 Aug 18
5 citations
Determining subpopulation methylation profiles from bisulfite sequencing data of heterogeneous samples using DXM
Jerry Fong, Jacob R. Gardner, Jared M. Andrews, Amanda F. Cashen, Jacqueline E. Payton, Kilian Q. Weinberger, John R. Edwards> ;Nucleic Acids Research. 2021 Sep 20
20 citations
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.
Jennifer A. Foltz, Brian T. Hess, Veronika Bachanova, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain, Michelle Becker-Hapak, Mark P. Foster, Timothy Scha...> ;Clinical Cancer Research. 2021 Jun 15
2 citations
Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma
Bita Fakhri, Elif Yilmaz, Feng Gao, Richard F. Ambinder, Richard Jones, Nancy L. Bartlett, Amanda F. Cashen, Nina Wagner-Johnston> ;Leukemia & Lymphoma. 2021 May 14
27 citations
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral ...
Patrick B. Johnston, Amanda F. Cashen, Petros Nikolinakos, Anne W. Beaven, Stefan K. Barta, Gajanan Bhat, Steven J. Hasal, Sven de Vos, Yasuhiro Oki, Changchun Deng, F...> ;Experimental Hematology & Oncology. 2021 Feb 18
2 citations
A Systemic Protein Deviation Score Linked to PD-1CD8T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma.
Eivind Heggernes Ask, Astrid Tschan-Plessl, Thea Johanne Gjerdingen, Michelle Lu Sætersmoen, Hanna Julie Hoel, Merete Thune Wiiger, Johanna Olweus, Björn E Wahlin, Ole...> ;Med. 2021 Feb 12
Join now to see all

Journal Articles

The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplan...
Amanda F Cashen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Improving Risk Stratification in Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia in ChildrenApril 21st, 2023
$11.5 Million Supports Innovation in Leukemia ResearchNovember 6th, 2018
Drug That Modifies Gene Activity Could Help Some Older Leukemia PatientsFebruary 12th, 2016